In addition, an anti-PRLR antibody-drug conjugate (ADC) had significant PRLR-specific antitumor activity against breast cancer [7], and bispecific antibody-ADCs bridging HER2 and PRLR improved efficacy of HER2 ADCs [8]. This evidence concerns the gene PRLR and breast cancer.